Page 45 - Read Online

Yagishita et al. J Cancer Metastasis Treat 2019;5:75 I http://dx.doi.org/10.20517/2394-4722.2019.026 Page 11 of 13

CONCLUSION
The pharmacogenomics of antibody drugs is a complex area with more relevant factors than small molecule
compounds. It is expected that pharmacogenomic factors related to drug efficacy and adverse events will
be identified by comprehensively analyzing not only PK and PD, but also multiple factors such as host
immune environment and genetic factors.

DECLARATIONS
Authors’ contributions
Wrote the manuscript and prepared the figures and tables: Yagishita S, Hamada A

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Frazer JK, Capra JD. Immunoglobulins: structure and function. Fundamental Immunology. 4th edition. New York: Lippincott-Raven; 1999.
pp. 37-74.
2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
3. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol
2010;10:328-43.
4. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005;5:447-58.
5. Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell 2018;9:15-32.
6. Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma-globulin catabolism. Nature 1964;203:1352-4.
7. Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 1966;2:1087-93.
8. Simister NE, Mostov KE. Cloning and expression of the neonatal rat intestinal Fc receptor, a major histocompatibility complex class I
antigen homolog. Cold Spring Harb Symp Quant Biol 1989;54 Pt 1:571-80.
9. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum
IgG from catabolism. J Immunol 2007;179:4580-8.
10. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25.
11. Sachs UJ, Socher I, Braeunlich CG, Kroll H, Bein G, et al. A variable number of tandem repeats polymorphism influences the transcriptional
activity of the neonatal Fc receptor alpha-chain promoter. Immunology 2006;119:83-9.
12. Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, et al. A genetic variation in the neonatal Fc-receptor affects anti-TNF drug
concentrations in inflammatory bowel disease. Am J Gastroenterol 2016;111:1438-45.
13. Passot C, Azzopardi N, Renault S, Baroukh N, Arnoult C, et al. Influence of FCGRT gene polymorphisms on pharmacokinetics of
therapeutic antibodies. MAbs 2013;5:614-9.
14. O'Shannessy DJ, Bendas K, Schweizer C, Wang W, Albone E, et al. Correlation of FCGRT genomic structure with serum immunoglobulin,
albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer. Genomics 2017;109:251-7.
15. Kaifu T, Nakamura A. Polymorphisms of immunoglobulin receptors and the effects on clinical outcome in cancer immunotherapy and other
immune diseases: a general review. Int Immunol 2017;29:319-25.
16. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-